Browse > Article
http://dx.doi.org/10.3345/kjp.2008.51.1.78

Outcome after relapse in childhood and adolescent osteosarcoma : single institution experience in Korea  

Lee, Yun-Jeong (Department of Pediatrics, Korean Cancer Center Hospital)
Lee, Hyun-Jae (Department of Pediatrics, Korean Cancer Center Hospital)
Kim, Dong-Ho (Department of Pediatrics, Korean Cancer Center Hospital)
Lim, Jung-Sub (Department of Pediatrics, Korean Cancer Center Hospital)
Lee, Jun-Ha (Department of Pediatrics, Korean Cancer Center Hospital)
Park, Kyung-Duk (Department of Pediatrics, Korean Cancer Center Hospital)
Jeon, Dae-Geun (Department of Orthopedics, Korean Cancer Center Hospital)
Lee, Soo-Yong (Department of Orthopedics, Korean Cancer Center Hospital)
Publication Information
Clinical and Experimental Pediatrics / v.51, no.1, 2008 , pp. 78-83 More about this Journal
Abstract
Purpose : Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. Although survival rate of osteosarcoma patients has markedly improved, about 20-30% of patients still have a relapse. This study was aimed to find factors that influence postrelapse survival of osteosarcoma in childhood and adolescents. Methods : Between 1985 and 2004, of 461 patients who were diagnosed and treated as osteosarcoma in Korean Cancer Center Hospital, 180 patients with recurrent osteosarcoma were retrospectively reviewed. We examined survival rates and analyzed prognostic factors, such as relapse site, post-relapse treatment methods, pathologic response to neoadjuvnat chemotherapy, metastasis at first diagnosis, and relapse free interval. Results : The overall recurrence rate of patients with osteosarcoma was 39%. The 5-year and 10-year postrelapse survival rates in the recurrent osteosarcoma were 13% and 4%, respectively. The 5-year post-relapse survival rate was influenced by site of relapse (lung, 39%; local, 0%; lung & bone, 25%; others, 12%; P<0.05), relapse-free interval (<12 months, 13%; ${\geq}12$ months, 44%, P<0.05), and post-relapse treatment methods (with surgery, 38%; without surgery, 11%; P<0.05). Conclusion : The survival rate of recurrent case is very low after 10 years, so new second-line chemotherapy and active treatment is needed to increase survival. Aggressive surgery with the removal of recurrence sites combined with multi-agent chemotherapy could either cure patients with recurrent osteosarcoma or significantly prolong their survival.
Keywords
Osteosarcoma; Recurrence; Survival rate;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 3rd ed. Philadelphia: Lippincott-Raven, 1997;889-920
2 Bacci G, Ferrari S, Bertoni F, Ruqqieri P, Picci P, Longhi A, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the IOR/OS2 protocol: an update report. J Clin Oncol 2000;18:4016-27
3 Jeon DG, Lee JS, Kim SJ, Gwak BJ, Cho WH, Lee SY. Osteosarcoma, survivorship following stage and chemotherapeutic regimen: 13 year experience of Korea Cancer Center Hospital. J Korean Orthop Assoc 1999;34:1027-34
4 Enneking WF. A system of grading musculoskeletal neoplasms. Clin Orthop 1986;204:9-24
5 Harvey JC, Lee K, Beattie EJ. Surgical management of pulmonary metastases. Chest Surg Clin N Am 1994;4:55-66
6 Snyder CL, Saltizman DA, Ferrell KL, Thompson RC, Leonard AS. A new approach to the resection of pulmonary osteosarcoma metastases. Clin Orthop 1991;270:247-53
7 Gentet JC, Brunat-Mentigny M, Demaille MC, Pein F, Avet-Loiseau H, Berger C, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the french society of paediatric oncology. Eur J Cancer 1997; 33:232-7   DOI   ScienceOn
8 Huth JF, Eilber FR. Patterns of recurrence after resection of osteosarcoma of the extremity: strategies for treatment of metastases. Arch Surg 1989;124:122-6   DOI   ScienceOn
9 Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the memorial sloan-kettering (T-12) protocol. J Clin Oncol 1998;16:2452-8   DOI
10 Koo HH, Jung HL, Dong ES, Ha SH, Park KD, Shin HY, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from 13-year experience in Seoul National University Hospital. Korean J Pediatr Hematol-Oncol 1994;1:122-35
11 Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tienghi A, et al. Postrelapse survival in osteosarcoma of the extremities. prognostic factors for long-term survival. J Clin Oncol 2003;21:710-5   DOI   ScienceOn
12 Goorin AM, Shuster JJ, Baker A, Horowitz ME, Meyer WH, Link MP. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multi-institutional osteosarcoma study. J Clin Oncol 1991;9:600-5   DOI
13 Kounami S, Nakayama K, Yoshiyama M, Yoshimasu T, Aoyagi N, Yoshikawa N, et al. Non-myeloablative allogenic peripheral blood stem cell transplantation in a patient with refractory osteosarcoma. Pediatr Transplant. 2005;9:342-5   DOI   ScienceOn
14 Beattie EJ. Surgical treatment of pulmonary metastases. Cancer 1984 54:2729-31   DOI   ScienceOn
15 Hunth JF, Holmes EC, Vernon SE, Callery CD, Ramming KP, Morton DL. Pulmonary resection for metastatic sarcoma. Am J Surg 1980;140:9-16   DOI   ScienceOn
16 Oh JH, Lee SH, Cho WS, Yoo KH, Kim JS, Gong HS, et al. Expression of p21, p27 in osteosarcoma and its prognostic significance. J Korean Bone Joint Tumor Soc 2003;9:169-77
17 Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP. Systemic relapse of patients with osteogenic sarcoma: prognostic factors for long term survival. Cancer 1995;75:1084-93   DOI   ScienceOn
18 Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977;101:14-8
19 Goorin AM, Delorey MJ, Lack EE, Gelber RD, Price K, Cassady JR, et al. Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol 1984;2:425-31   DOI
20 Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the european osteosarcoma intergroup. J Natl Cancer Inst 2007;17:112-28
21 Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoon A, Holmes EC, et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 1994;12:1849-58   DOI
22 Bielack S, Kempf-Bielack B, Schwenzer D, Birkfellner T, Delling G, Ewerbeck V, et al. Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the cooperative osteosarcoma study group COSS of 925 patients. Klin Padiatr 1999;211:260-70   DOI
23 Lee SH, Kim HS, Oh JH, Suh SW, Cho HS, Yoo JH, et al. Analysis of survival and prognostic factors in patients of pulmonary metastasis from osteosarcoma. J Korean Orthop Assoc 2004;39:50-5   DOI
24 Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a clinical review. J Clin Oncol 1994;12:423-31   DOI
25 Beron G, Euler A, Winkler K. Pulmonary metastases from osteogenic sarcoma: complete resection and effective chemotherapy contributing to improved prognosis. Eur Paediatr Haematol Oncol 1985;2:77-85   DOI
26 Spanos PK, Payne WS, Ivins JC, Pritchard DJ. Pulmonary resection for metastatic osteogenic sarcoma. J Bone Joint Surg 1976;58:624-8   DOI
27 Todesco A, Carli M, Iacona I, Frascella E, Ninfo V, Rosolen A. All-trans retinoic acid and interferon-alpha in the treatment of a patient with resistant metastatic osteosarcoma. Cancer 2000;15:2661-6
28 Fuchs N, Bielack S, Epler D, Bieling P, Delling G, Korliolz D, et al. Long-term results of the co-operative germanaustrian-swiss osteosarcoma study group's protocol COSS- 86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998;9:893-9   DOI   ScienceOn
29 Jeffree GM, Price HG, Sissons HA. The metastatic pattern of osteosarcoma. Cancer 1975;32:87-107   DOI   ScienceOn
30 Skinner KA, Eilber FR, Holmes EC, Eckardt J, Rosen G. Surgical treatment and chemotherapy for pulmonary metastases from osteosarcoma. Arch Surg 1992;127:1065-71   DOI   ScienceOn